BC-designed skin cancer detection technology now in use

Issue: BCMJ, vol. 55, No. 6, July August 2013, Page 295 News

A locally developed, noninvasive skin cancer detection technology is now available in Canada, Europe, and Australia for use by dermatologists and GPs with a special interest in skin cancer. The device, called the Verisante Aura, has been installed in four dermatology clinics across Canada so far—in Vancouver, Calgary, Edmonton, and Oakville. 

The Verisante Aura was developed by researchers and dermatologists at the BC Cancer Agency and the UBC Faculty of Medicine. The device uses laser technology (Raman spectroscopy) to scan a mole or lesion to detect cancerous cells.

Raman spectroscopy detects skin cancer by creating vibrations in the molecules of the skin. Cancerous cells vibrate differently than noncancerous cells, and these differences in vibration are measured by the laser using 21 biomarkers to identify skin cancer with a 99% accuracy rate. The device can be easily operated by a GP or a trained office staff member, and can scan every mole on a patient’s body in 15 minutes.

This homegrown innovation won the 2011 “Best of What’s New” award from Popular Science, a 2013 Prism Award for Photonics Innovation from SPIE and Photonics Media, and the 2013 Bronze Edison Award for innovation. The device promises to speed the diagnostic process, avoid unnecessary biopsies, and detect skin cancer early in its most treatable stages.

The use of Raman spectroscopy to detect and diagnose skin cancer was reviewed in an article entitled “Real-time Raman spectroscopy for in vivo skin cancer diagnosis,” published in the May 2012 issue of Cancer Re­search. The article can be viewed at http://cancerres.aacrjournals.org/content/72/10/2491.short. 

For more information on the device and how it can be incorporated into physician offices visit the Veri­sante Aura website, www.verisante.com/aura/medical_professional.

. BC-designed skin cancer detection technology now in use . BCMJ, Vol. 55, No. 6, July, August, 2013, Page(s) 295 - News.


Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.


For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org

BCMJ Guidelines for Authors

Leave a Reply